In a striking revelation, internal records have uncovered a meeting between top officials at the Environmental Protection Agency (EPA) and Bayer’s CEO, Bill Anderson, held on 17 June 2025. This encounter focused on “litigation” matters related to glyphosate, a controversial herbicide at the centre of numerous cancer lawsuits, just months before the Trump administration took significant steps to bolster Bayer’s legal position in the Supreme Court.
A Key Meeting with Major Implications
Documents obtained through a Freedom of Information Act request indicate that the meeting included Lee Zeldin, the EPA’s administrator, and several other senior officials. The agenda reportedly covered “supreme court action” aimed at addressing ongoing litigation that has seen Bayer facing claims from thousands of individuals alleging that their cancers were linked to the use of glyphosate-based products like Roundup.
Bayer is grappling with a substantial financial burden due to these lawsuits, which have already led to billions in settlements. The company’s strategy hinges on persuading the Supreme Court that, because the EPA does not mandate a cancer warning on glyphosate products, Bayer should not be held liable for failing to issue such warnings.
Regulatory Support Following the Meeting
Since this pivotal meeting, the Trump administration has exhibited a series of actions that appear to favour Bayer’s interests. In December 2025, D John Sauer, appointed by the Trump administration as solicitor general, urged the Supreme Court to accept Bayer’s case, which it subsequently agreed to hear. Furthermore, in February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, effectively providing immunity to manufacturers like Bayer.
On 2 March 2026, Sauer filed an amicus brief supporting Bayer in the Supreme Court, marking a concerted effort by the government to bolster the company’s legal standing. This series of actions has raised alarms among critics who argue that the interests of corporate entities are being privileged over public health concerns.
Responses from Advocacy Groups and Experts
Environmental advocates have expressed deep concern regarding the implications of such high-level discussions. Nathan Donley, director of environmental health science for the Center for Biological Diversity, stated, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” This sentiment is echoed by other experts who highlight the troubling nature of corporate access to regulatory bodies.
Whitney Di Bona, a consumer safety advocate, remarked on the imbalance in who gets to voice concerns at these meetings. “We should also ask whether the agency gave the same chance to speak to the thousands of people who say they got cancer after using Roundup,” she noted.
Naomi Oreskes, a Harvard professor studying corporate influence on regulation, described the meeting as indicative of a broader pattern where industry leaders enjoy privileged access to government officials, often at the expense of public interest.
Zen Honeycutt, founder of Moms Across America, added, “Coercion by chemical companies on our regulatory agencies is nothing new,” underscoring the long-standing concerns regarding corporate influence over environmental regulations.
Why it Matters
The unfolding situation surrounding Bayer, glyphosate, and the EPA raises significant questions about the integrity of regulatory processes in the face of corporate influence. As the legal battle continues, the implications extend beyond Bayer’s financial concerns; they touch on public health, consumer safety, and the fundamental role of government agencies in protecting citizens. The outcome of Bayer’s Supreme Court case could set a precedent that shapes the landscape of environmental safety regulations and corporate accountability for years to come.
